NCT02273635 - Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

April 30, 2017

Conditions

Primary Progressive Multiple SclerosisMultiple Sclerosis, Secondary Progressive

Interventions

DRUG

Andrographolides

140 mg andrographolides coated tablets twice a day orally administered for 24 months.

DRUG

placebo

140 mg excipients coated tablets twice a day orally administered for 24 months

Trial Locations (1)

RECRUITING

Multiple Sclerosis Centre, Pontificia Universidad Catolica de Chile, Santiago